title: Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis.
authors.forename: Ken
authors.initials: K
authors.lastname: Garber
mesh_terms: D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000201:enzymology; D017326:Clinical Trials, Phase III as Topic; D016503:Drug Delivery Systems; D004345:Drug Industry; D006801:Humans; D007165:Immunosuppression Therapy; D053612:Janus Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics; D010880:Piperidines; D011743:Pyrimidines / Q000494:pharmacology*; D011758:Pyrroles / Q000494:pharmacology*; D018121:Receptors, Cytokine / Q000378:metabolism; D015398:Signal Transduction
chemical_list: D010880:Piperidines; D011743:Pyrimidines; D011758:Pyrroles; D018121:Receptors, Cytokine; C479163:tofacitinib; D053612:Janus Kinases